# HARMONi-GI3 (NCT07228832)

> Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07228832
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Summit Therapeutics
- Conditions: Metastatic Colorectal Cancer (CRC)
- Interventions: Drug: Ivonescimab Injection; Drug: Bevacizumab Injection
- Enrollment: 600
- Primary outcome: PFS by IRRC based on RECIST v1.1

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 4
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=harmoni-gi3-nct07228832